Bullfrog AI Holdings, Inc. Common Stock (BFRG) EBITDA: History & Chart

Bullfrog AI Holdings, Inc. Common Stock(BFRG)

Medical - Healthcare Information Services · Gaithersburg, MD

$0.59-0.02 (-3.81%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Bullfrog AI Holdings, Inc. Common Stock

BullFrog AI Holdings, Inc., along with its affiliated entities, functions as an advanced digital biopharmaceutical firm. Its core mission involves harnessing artificial intelligence and machine learning (AI/ML) to process and interpret extensive medical and healthcare datasets specifically within the United States. A central offering is bfLEAP, a proprietary AI/ML platform meticulously crafted for the thorough examination of both preclinical and clinical research data. The company has also secured critical intellectual property through licensing agreements. One such accord, with George Washington University, provides rights to utilize siRNA targeting Beta2-spectrin. This technology is being investigated for its therapeutic potential across a spectrum of human conditions, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Additionally, a partnership with Johns Hopkins University grants access to a distinct Mebendazole formulation, developed for the treatment of various human cancers or neoplastic diseases. Founded in 2017, BullFrog AI Holdings, Inc. operates from its headquarters in Gaithersburg, Maryland.

Gaithersburg, MD

9 employees

www.bullfrogai.com

Healthcare / Medical - Healthcare Information Services

Sector: Healthcare
Industry: Medical - Healthcare Information Services
CEO: Vininder Singh

View full financials

EBITDA

The latest quarterly EBITDA is −$1.42 Million with a QoQ Growth of +12.12%. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) measures a company's operating performance by removing non-cash charges and capital structure effects.

Q2 FY2026 (2026-06-30).

Depreciation|Operating Income|Net Income|Free Cash Flow|Income Statement

EBITDA

BFRG EBITDA

$-1.42M

Reported quarterly EBITDA; no daily interpolation. Q2 FY2026 (2026-06-30): $-1.42M.

-663.61% over 10Y

BFRG Quarterly EBITDA Growth (YoY)

EBITDA growth vs the same fiscal quarter in the prior fiscal year, last 16 comparable quarters.

Current EBITDA

−$1.42M

−$1.42 Million

Q2 FY2026 · 2026-06-30

QoQ Growth

+12.12%

vs. −$1.61M prior quarter

Historical Data

Quarters of data available

Quarterly EBITDA History

Period	EBITDA	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	−$1.42M	+12.12%	+3.44%
Q1 FY2026Period end 2026-03-31	−$1.61M	-7.74%	+21.50%
Q4 FY2025Period end 2025-12-31	−$1.50M	+4.53%	+15.27%
Q3 FY2025Period end 2025-09-30	−$1.57M	-6.81%	+13.75%
Q2 FY2025Period end 2025-06-30	−$1.47M	+28.55%	+12.62%
Q1 FY2025Period end 2025-03-31	−$2.06M	-16.28%	-4.63%
Q4 FY2024Period end 2024-12-31	−$1.77M	+2.81%	-32.43%
Q3 FY2024Period end 2024-09-30	−$1.82M	-8.21%	-39.56%
Q2 FY2024Period end 2024-06-30	−$1.68M	+14.44%	-9.44%
Q1 FY2024Period end 2024-03-31	−$1.97M	-47.18%	-65.12%
Q4 FY2023Period end 2023-12-31	−$1.34M	-2.43%	-129.20%
Q3 FY2023Period end 2023-09-30	−$1.30M	+15.15%	-103.67%
Q2 FY2023Period end 2023-06-30	−$1.54M	-29.10%	-125.37%
Q1 FY2023Period end 2023-03-31	−$1.19M	-104.29%	-116.30%
Q4 FY2022Period end 2022-12-31	−$582.60K	+8.98%	N/A
Q3 FY2022Period end 2022-09-30	−$640.11K	+6.11%	-272.71%
Q2 FY2022Period end 2022-06-30	−$681.79K	-23.91%	-266.99%
Q1 FY2022Period end 2022-03-31	−$550.25K	N/A	N/A
Q4 FY2021Period end 2021-12-31	−$141.24K	+17.76%	N/A
Q3 FY2021Period end 2021-09-30	−$171.74K	+7.56%	N/A
Q2 FY2021Period end 2021-06-30	−$185.78K	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.

Data as of June 30, 2026

EBITDA

BFRG EBITDA

BFRG Quarterly EBITDA Growth (YoY)

Current EBITDA

QoQ Growth

Historical Data

Quarterly EBITDA History

Related Metrics